Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care: an Open-label Phase 1/2 Proof-of-concept, Feasibility, and Dose-finding Clinical Trial
Sponsor: Bruyère Continuing Care
This PHASE1/PHASE2 trial investigates Delirium of Mixed Origin and Hyperactive Delirium and is currently actively recruiting participants. Bruyère Continuing Care leads this study, which shows 9 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jan 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Jan 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
May 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bruyère Continuing Care
- Bruyère Health Research Institute.
- Foothills Medical Centre
- The Ottawa Hospital
For direct contact, visit the study record on ClinicalTrials.gov .